Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03244085
Registration number
NCT03244085
Ethics application status
Date submitted
28/07/2017
Date registered
9/08/2017
Date last updated
16/07/2018
Titles & IDs
Public title
A Study to Investigate the Safety, Efficacy and Pharmacokinetic Profile of Multiple Doses of QL-007 in Chronic Hepatitis B Patients
Query!
Scientific title
An Open-Label Phase 1b Study to Evaluate the Dose-Related Safety, Efficacy, and Pharmacokinetic Profile of Different Doses of QL-007 in Chronic Hepatitis B Patients
Query!
Secondary ID [1]
0
0
QL007-002
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Chronic Hepatitis b
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - QL-007 tablet
Experimental: 100 mg BID - Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (100 mg two times a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
Experimental: 200 mg BID - Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (200 mg two times a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
Experimental: 600 mg QD - Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (600 mg once a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
Treatment: Drugs: QL-007 tablet
Patients will be enrolled in 1 of 3 cohorts (6 patients per cohort): QL 007 200 mg/day (100 mg BID), or QL 007 400 mg/day (200 mg/BID), or QL 007 600 mg QD. QL 007 will be administered orally daily over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Incidence of Adverse Events of QL-007
Query!
Assessment method [1]
0
0
Safety assessments will include adverse events, clinical safety laboratory parameters, vital signs, physical examinations, and electrocardiogram results.
Query!
Timepoint [1]
0
0
From randomization up to Day 36
Query!
Secondary outcome [1]
0
0
Peak Plasma Concentration (Cmax) of QL-007 following multiple doses
Query!
Assessment method [1]
0
0
Concentrations of QL-007 in plasma will be collected on Day 1, Day 3, Day 8, Day 15, Day 22 and Day 28.
Query!
Timepoint [1]
0
0
On Day 1, Day 3, Day 8, Day 15, Day 22 and Day 28, samples will be collected pre-dose; on Day 1 and 28, samples will also be collected at 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h and 12h post dose.
Query!
Secondary outcome [2]
0
0
The time to Cmax (tmax) of QL-007 following multiple doses
Query!
Assessment method [2]
0
0
Concentrations of QL-007 in plasma will be collected on Day 1, Day 3, Day 8, Day 15, Day 22 and Day 28.
Query!
Timepoint [2]
0
0
On Day 1, Day 3, Day 8, Day 15, Day 22 and Day 28, samples will be collected pre-dose; on Day 1 and 28, samples will also be collected at 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h and 12h post dose.
Query!
Secondary outcome [3]
0
0
AUC0-t (area under the plasma concentration versus time curve) of QL-007 following multiple doses
Query!
Assessment method [3]
0
0
Concentrations of QL-007 in plasma will be collected on Day 1, Day 3, Day 8, Day 15, Day 22 and Day 28.
Query!
Timepoint [3]
0
0
On Days 1, 3, 8, 15, 22 and 28, samples will be collected pre-dose; on Day 1 and 28, samples will also be collected at 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h and 12h post dose.
Query!
Secondary outcome [4]
0
0
AUC0-8 of QL-007 following multiple doses
Query!
Assessment method [4]
0
0
Concentrations of QL-007 in plasma will be collected on Day 1, Day 3, Day 8, Day 15, Day 22 and Day 28.
Query!
Timepoint [4]
0
0
On Day 1, Day 3, Day 8, Day 15, Day 22 and Day 28, samples will be collected pre-dose; on Day 1 and 28, samples will also be collected at 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h and 12h post dose.
Query!
Secondary outcome [5]
0
0
t1/2 (terminal elimination half-life) of QL-007 following multiple doses
Query!
Assessment method [5]
0
0
Concentrations of QL-007 in plasma will be collected on Day 1, Day 3, Day 8, Day 15, Day 22 and Day 28.
Query!
Timepoint [5]
0
0
On Day 1, Day 3, Day 8, Day 15, Day 22 and Day 28, samples will be collected pre-dose; on Day 1 and 28, samples will also be collected at 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h and 12h post dose.
Query!
Secondary outcome [6]
0
0
Vz/F(apparent volume of distribution for the terminal disposition phase) of QL-007 following multiple doses
Query!
Assessment method [6]
0
0
Concentrations of QL-007 in plasma will be collected on Day 1, Day 3, Day 8, Day 15, Day 22 and Day 28.
Query!
Timepoint [6]
0
0
On Day 1, Day 3, Day 8, Day 15, Day 22 and Day 28, samples will be collected pre-dose; on Day 1 and 28, samples will also be collected at 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h and 12h post dose.
Query!
Secondary outcome [7]
0
0
CL/F (apparent clearance) of QL-007 following multiple doses
Query!
Assessment method [7]
0
0
Concentrations of QL-007 in plasma will be collected on Day 1, Day 3, Day 8, Day 15, Day 22 and Day 28.
Query!
Timepoint [7]
0
0
On Day 1, Day 3, Day 8, Day 15, Day 22 and Day 28, samples will be collected pre-dose; on Day 1 and 28, samples will also be collected at 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h and 12h post dose.
Query!
Secondary outcome [8]
0
0
Change in serum HBsAg from baseline at Day 1, Day 3, Day 8, Day 15, Day 22 and Day 28
Query!
Assessment method [8]
0
0
To evaluate serum levels of HBsAg, multiple blood samples will be drawn as specified in the Schedule of Assessments. Blood samples will be collected into <[specify type of tube]> tubes during screening and on Day -1; prior to investigational product administration on Days1, 3, 8, 15, 22, 28; and on the follow-up 7 ±1 days after the last dose of the investigational product.
Query!
Timepoint [8]
0
0
Day 1, Day 3, Day 8, Day 15, Day 22 and Day 28
Query!
Secondary outcome [9]
0
0
Change in serum HBV DNA from baseline at Day3, 8, 15, 22 and 28
Query!
Assessment method [9]
0
0
To evaluate serum levels of HBV DNA, multiple blood samples will be drawn as specified in the Schedule of Assessments. Blood samples will be collected into <[specify type of tube]> tubes during screening and on Day -1; prior to investigational product administration on Days 1, 3, 8, 15, 22, 28; and on the follow-up 7 ±1 days after the last dose of the investigational product.
Query!
Timepoint [9]
0
0
Day 1, Day 3, Day 8, Day 15, Day 22 and Day 28
Query!
Eligibility
Key inclusion criteria
1. Adult (age 18-65 years inclusive) males or females with chronic HBV (positive for
serum hepatitis B surface antigen (HBsAg) or HBV DNA for = 6 months) prior to
baseline.
2. Anti-HBV treatment-naive adults; adults who have taken oral anti-HBV nucleoside
therapy with the last dose = 4 weeks prior to screening are also eligible.
3. Positive or negative for hepatitis B e antigen (HBeAg).
4. HBV DNA = 20,000 IU/mL.
5. ALT levels could be normal or elevated to < 10 times upper limit of normal.
6. Creatinine clearance = 70 mL/min.
7. The following laboratory criteria have been met:
- Absolute neutrophil count (ANC) = 1.5 x 109/L
- Hemoglobin (Hgb) = 8 g/dL
- Platelets = 75 x 109/L
8. Negative serum pregnancy test for females of childbearing potential
9. For men and women who are not postmenopausal (ie, = 12 months of non-therapy-induced
amenorrhea, confirmed by follicle stimulating hormone (FSH), if not on hormone
replacement) or surgically sterile (vasectomy in males or absence of ovaries and/or
uterus or tubal ligation in females) agreement to remain abstinent or use a highly
effective method of contraception during the treatment period and at least through
week 12 after last dose.
10. Participants must have signed an ICF indicating that they understand the purpose of
and procedures required for the study and are willing to participate in the study and
comply with the study procedures and restrictions.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria
Patients will be excluded from the study if one or more of the following criteria are
applicable:
1. Known co-infection with HIV, hepatitis C virus (HCV) or hepatitis D virus (HDV)
2. Presence of autoimmune disorders
3. History of liver disease other than Hepatitis B
4. History of Gilbert's Disease
5. Any sign of decompensated liver disease
6. Known or suspected cirrhosis
7. Evidence of hepatocellular carcinoma
8. Patient has clinically significant, uncontrolled heart disease and/or recent cardiac
event (within 6 months), such as:
- unstable angina within 6 months prior to screening;
- myocardial infarction within 6 months prior to screening;
- history of documented congestive heart failure (New York Heart Association
functional classification III-IV);
- uncontrolled hypertension defined by a systolic blood pressure (SBP) = 160 mm Hg
and/or diastolic blood pressure (DBP) = 100 mm Hg, with or without
antihypertensive medication;
- initiation or adjustment of antihypertensive medication(s) is allowed prior to
screening;
- ventricular arrhythmias; supraventricular and nodal arrhythmias not controlled
with medication;
- other cardiac arrhythmia not controlled with medication;
- corrected QTc > 450 msec using Fridericia correction on the screening ECG.
9. Electrolyte abnormalities.
10. Impaired GI function or GI disease that may alter absorption of QL-007.
11. Ongoing GI AEs > grade 2 (eg, nausea, vomiting, or diarrhea) at screening.
12. Receiving medications that meet one of the following criteria and that cannot be
discontinued = 1 week prior to the start of treatment QL 007:
- Medication with a known risk of prolonging the QT interval or inducing Torsades
de Pointes (see Appendix 3; please refer to
https://crediblemeds.org/pdftemp/pdf/CombinedList.pdf
- Moderate or strong inhibitors or strong inducers of CYP3A (please refer to
http://medicine.iupui.edu/flockhart/table.htm or
http://www.druginteractioninfo.org)
- Unstable or increasing doses of corticosteroids
- Enzyme-inducing anticonvulsive agents
- Herbal supplements.
13. Alcohol or substance abuse
14. History of bleeding diathesis
15. Patients with a history of seizures, central nervous system disorders or psychiatric
disability thought to be clinically significant in the opinion of the investigator.
16. History of clinically significant gastrointestinal, cardiovascular, endocrine, renal,
ocular, pulmonary, psychiatric or neurological disease.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Unknown status
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
20/08/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/12/2018
Query!
Actual
Query!
Sample size
Target
18
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
New Zealand
Query!
State/province [1]
0
0
Wellington
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Qilu Pharmaceutical Co., Ltd.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a nonrandomized, open-label, no-control, dose-escalation Phase 1b trial in 18
patients with chronic HBV infection to determine the safety, preliminary efficacy, and
pharmacokinetics (PK) of QL-007 after administration over 28 days of multiple oral doses in a
fasted state at the following planned dose levels: 200 mg/day (100 mg two times a day (BID)),
400 mg/day (200 mg BID), then 600 mg once daily (QD), with 6 patients for each cohort.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03244085
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03244085
Download to PDF